



WELCURE DRUGS & PHARMACEUTICALS LTD.

Regd. Off. : B-9 & 10, Laxmi Towers, L.S.C., Block C, Saraswati Vihar, Delhi -110034.
CIN No. L24232DL1996PLC227773

Date: 25.10.2021

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400001

Scrip Code: 524661--Welcure Drugs & Pharmaceuticals Ltd.

Sub: Un-audited Financial Results for the Quarter and half year ended 30.09.2021

Ref: Outcome of Board of Directors Meeting- 25th October, 2021

Respected Sir,

Pursuant to the provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held today Monday, 25th October, 2021 at 11:30 am and concluded at 12:50 pm, *inter-alia*, approved the Un-audited Financial Results of the Company for the Quarter and half year ended 30th September, 2021.

We enclose copies of the following:

1. Un-audited Financial Results for the quarter and half year ended 30th September, 2021; and
2. Limited Review Report of Un-Audited Financial Results for the said period.

We request you to take the same on record.

Thanking you

Yours faithfully

For Welcure Drugs & Pharmaceuticals Limited


(Mitashi Bisaria)

Director & Company Secretary
DIN: 08660802



Encl.: a/a

V.P GUPTA & CO.

Chartered Accountants

288, GHALIB APPARTMENTS, PARWANA ROAD, PITAMPURA, DELHI-110034. PH.:27020321, 9313675632

EMAIL-info@vpguptaandco.com

LIMITED REVIEW REPORT

(For the Quarter & Half Year ended on September 30, 2021)

To
**The Board of Directors,
Welcure Drugs & Pharmaceuticals Limited**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Welcure Drugs & Pharmaceuticals Limited ("the Company") for the Quarter & Half year ended September 30, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("the Regulations") as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular")
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors on 25th October, 2021 has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind-AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditors of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies



Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, that has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.

Place: Delhi
Date: 25.10.2021

For V.P. Gupta & Co.
Chartered Accountants

FRN: 000699N



CA V.P Gupta
Partner

M No.: 080557

UDIN: 21080557AAAACX9656

WELCURE DRUGS AND PHARMACEUTICALS LTD							
Regd. Office: B-9& 10, Laxmi Towers LSC, C-Block, Saraswati Vihar, Delhi-110034							
CIN: L24232DL1996PLC227773							
Email Id: investor.welcure@gmail.com							
Statement of Unaudited Financial Results for the Quarter & Half year ended 30th September, 2021							
S. No.	Particulars	(Figures in Lakhs)					
		Quarter Ended			Half Year Ended		Year ended
		30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	31-Mar-21
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I	Income						
	a) Revenue from operations	-	-	-	-	-	-
	b) Other Operating Income	-	2.25	3.03	2.25	8.13	13.33
	Total Income from operations (net)	-	2.25	3.03	2.25	8.13	13.33
II	Other Income		-	0.06		0.06	0.02
III	Total Income (I+II)	-	2.25	3.09	2.25	8.19	13.35
IV	Expenses						
	(a) Cost of raw materials consumed	-	-	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefits expenses	0.36	0.21	0.21	0.57	0.42	0.84
	(e) Finance Cost	-	-	-	-	-	-
	(f) Depreciation and amortisation expense	-	-	-	-	-	-
	(g) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	0.99	4.44	1.53	5.43	5.85	7.00
	Total Expenses	1.35	4.65	1.74	6.00	6.27	7.84
V	Profit/ (Loss) Before Exceptional and Extraordinary Items and Tax (III-IV)	(1.35)	(2.40)	1.35	(3.75)	1.92	5.51
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/ (Loss) before extraordinary items and Tax (V-VI)	(1.35)	(2.40)	1.35	(3.75)	1.92	5.51
VIII	Extraordinary Items	-	-	-	-	-	-
IX	Profit before tax (VII- VIII)	(1.35)	(2.40)	1.35	(3.75)	1.92	5.51
X	Tax Expenses						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
XI	Profit (Loss) for the period from continuing operations (IX-X)	(1.35)	(2.40)	1.35	(3.75)	1.92	5.51
XII	Net Profit/ (Loss) from discontinuing operation (before Tax)	-	-	-	-	-	-
XIII	Tax Expense of discontinuing operations	-	-	-	-	-	-
XIV	Net Profit/ (Loss) from discontinuing operation after Tax (XII-XIII)	-	-	-	-	-	-
XV	Net Profit/ (Loss) for the Period (XI+XIV)	(1.35)	(2.40)	1.35	(3.75)	1.92	5.51
XVI	Share of profit / (loss) of associates	-	-	-	-	-	-
XVII	Share of profit / (loss) of Minority	-	-	-	-	-	-
XVIII	Net Profit/ (Loss) after taxes, minority interest and share of profit/(loss) of associates	(1.35)	(2.40)	1.35	(3.75)	1.92	5.51
XIX	Other Comprehensive Income	-	-	-	-	-	-
XX	Total Comprehensive Income for the period (XVIII+XIX)	(1.35)	(2.40)	1.35	(3.75)	1.92	5.51
XXI	Paid-up share capital (Face value of Rs.10/- per share)	1,211.86	1,211.86	1,211.86	1,211.86	1,211.86	1,211.86
XXII	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-			(1,204.92)
XXIII	Earning Per Share (of Rs. 10/- each) (not annualised)	(0.01)	(0.02)	0.01	(0.03)	0.02	0.05
	A) Basic						
	B) Diluted						

Notes:

- The Statement of Unaudited Financial results for the Quarter & Half year ended September 30, 2021 have been reviewed by the audit committee and approved by the Board of directors at their respective meetings held on 25th October, 2021. There are no qualifications in Limited Review Report issued by the auditor.
- The financial results for the quarter and half year ended September 30, 2021 have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- There were no investor complaints pending during the Quarter ended September 30, 2021
- As the Company is mainly operating in one reportable business segment, hence the disclosure requirements of Indian Accounting Standard (Ind AS-108) "Operating Segment" is not applicable.
- The Previous Quarter ended figures have been re-grouped/ re-arranged, whenever necessary.
- There is no need to provide any reconciliation as required by the circular dated July 05, 2016, since there is no change in the figures due to transit from the previous Indian GAAP to Ind-AS.

Place: Delhi
Date: 25.10.2021



For WELCURE DRUGS & PHARMACEUTICALS LIMITED

SUDHIR CHANDRA
MANAGING DIRECTOR
DIN: 00323545

WELCURE DRUGS AND PHARMACEUTICALS LTD			
Regd. Office: B-9& 10, Laxmi Towers LSC, C-Block, Saraswati Vihar, Delhi-110034			
CIN: L24232DL1996PLC227773			
Email Id: investor.welcure@gmail.com			
Statement of Assets and Liabilities			
	Particulars	30-09-2021 (Un-audited)	(Figures in Lakhs) 31-03-2021 (Audited)
A	ASSETS		
I	Non-current assets		
	(a) Property, Plant & Equipment	-	-
	(b) Capital Work-in-Progress	-	-
	(c) Goodwill	-	-
	(d) Other Intangible Assets	-	-
	(e) Financial Assets		
	(i) Investments	-	-
	(ii) Loans	-	-
	(iii) Other Financial Assets	-	-
	(f) Other Non current Assets	-	-
	(g) Deferred Tax Assets	-	-
	Subtotal- Non-current assets	-	-
II	Current assets		
	(a) Inventories	-	-
	(b) Financial Assets		
	(i) Loans	-	-
	(ii) Cash and Cash Equivalents	0.93	4.75
	(iii) Other Bank Balances	-	-
	(iv) Trade Receivables	-	-
	(v) Other Financial Assets	-	-
	(c) Other Current Assets	-	-
	(d) Current Tax Assets	2.67	2.55
	Subtotal- Current assets	3.60	7.30
	TOTAL - ASSETS	3.60	7.30
B	EQUITY AND LIABILITIES		
I	Equity		
	(a) Equity Share Capital	1,211.86	1,211.86
	(b) Other Equity	(1,208.67)	(1,204.92)
	Subtotal- Equity	3.19	6.94
II	Liabilities		
(i)	Non-current liabilities		
	(a) Financial Liabilities	-	-
	(b) Provisions	-	-
	(c) Deferred Tax Liabilities	-	-
	(d) Other Non-Current Liabilities	-	-
	Subtotal- Non-current liabilities	-	-
(ii)	Current liabilities		
	(a) Financial Liabilities		
	(i) Loans	-	-
	(ii) Trade Payables	-	-
	(iii) Other Financial Liabilities	0.41	0.36
	(b) Other current Liabilities	-	-
	(c) Current Tax Liabilities	-	-
	(d) Short-term provisions	-	-
	Subtotal- Current liabilities	0.41	0.36
	TOTAL - EQUITY AND LIABILITIES	3.60	7.30

Place: New Delhi
Date: 25.10.2021

For WELCURE DRUGS & PHARMACEUTICALS LIMITED



SUDHIR CHANDRA
MANAGING DIRECTOR
DIN: 00323545

WELCURE DRUGS AND PHARMACEUTICALS LTD

Regd. Office: B-9& 10, Laxmi Towers LSC, C-Block, Saraswati Vihar, Delhi-110034

CIN: L24232DL1996PLC227773

Email Id: investor.welcure@gmail.com

Cash Flow Statement for the period ended September 30, 2021

		(Figures in Lakhs)	
Particulars		30-09-2021 (Un-audited)	31-03-2021 (Audited)
A. Cash Flow from Operating Activities			
Net Profit/(Loss) before tax		(3.75)	5.51
Operating Profit before working capital changes		(3.75)	5.51
Adjustments for working capital changes			
Other Assets		(0.12)	(0.62)
Other Financial Liabilities		0.05	(0.61)
Other Current Liabilities		-	(0.06)
Cash generated from operations		(3.82)	4.22
Net Cash flow from/(used in) Operating Activities	(A)	(3.82)	4.22
B. Cash Flow from Investing Activities			
Net Cash flow from Investing Activities	(B)	-	-
C. Cash Flow from Financing Activities			
Net Cash flow from Financing Activities	(C)	-	-
Net Increase/(decrease) in Cash and Cash Equivalents	(A+B+C)	(3.82)	4.22
Cash and Cash Equivalents(Opening Balance)		4.75	0.53
Cash and Cash Equivalents(Closing Balance)		0.93	4.75
Change in cash and cash equivalents		(3.82)	4.22
		-	-

Place: New Delhi

Date: 25.10.2021

For WELCURE DRUGS & PHARMACEUTICALS LIMITED



SUDHIR CHANDRA
MANAGING DIRECTOR
DIN:00323545